Celyad, Medisun International deal

Celyad granted Medisun rights to commercialize C-Cure in Taiwan and China, including Hong Kong and Macau. Under the 15-year deal, Celyad is eligible for royalties of 10-30% on revenues and for profit sharing on 20-25% of revenues less royalties. Medisun will provide a minimum of EUR20 million ($22.3 million) for Celyad to conduct clinical development and submit regulatory applications in the region. ...